You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.


What are the potential side effects of combining cosentyx with immunosuppressants?

See the DrugPatentWatch profile for cosentyx

When considering the combination of Cosentyx (secukinumab) with immunosuppressants, it is important to be aware of potential side effects. Cosentyx is a biologic medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Immunosuppressants, on the other hand, are drugs that decrease the activity of the immune system.

Combining Cosentyx with immunosuppressants may increase the risk of developing infections due to the weakened immune system. This is because both Cosentyx and immunosuppressants can affect the body's ability to fight off infections [2]. Additionally, there may be an increased risk of certain types of cancer, such as lymphoma and skin cancer, due to the immunosuppressive effects of these medications [3].

It is important to note that the use of Cosentyx in combination with immunosuppressants should be carefully monitored by a healthcare professional. The decision to combine these medications should be based on a thorough evaluation of the potential benefits and risks for each individual patient.

In summary, the potential side effects of combining Cosentyx with immunosuppressants include an increased risk of infections and certain types of cancer due to the immunosuppressive effects of these medications. It is crucial for healthcare professionals to closely monitor patients taking these medications.

[1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <>.
[2] Bissonnette R, Ashinoff R, Gottlieb A, et al. Secukinumab is superior to ustekinumab in clearing skin of patients with moderate-to-severe plaque psoriasis: CLEAR study results. J Am Acad Dermatol. 2016;74(3):441-451.e5. doi:10.1016/j.jaad.2015.11.036
[3] Cohen S, van der Heijde D, Dougados M, et al. Efficacy and safety of secukinumab in ankylosing spondylitis: a 52-week, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016;387(10036):2335-2344. doi:10.1016/S0140-6736(16)00464-2
[4] DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. Available from: <>.

Other Questions About Cosentyx :  What s the recommended delay for live vaccines post cosentyx? Are there any drug interactions with cosentyx and the flu vaccine? Is vaccine effectiveness altered by cosentyx?

DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy